NOX 5.71% 6.6¢ noxopharm limited

Patent progress

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    On 29 December 2019, Noxopharm submitted a powerful rebuttal of every point raised by the US Patent Examiner for the patent application called Radiotherapy Improvements, and concluded thus:

    Summary
    In summary, applicant submits that the prior art does not disclose a formulation comprising Idronoxil that would be capable of being delivered to the CNS, let alone treating brain cancer … Reconsideration and withdrawal of the rejection is therefore respectfully requested.


    Conclusion
    In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance and an early notification to that effect is earnestly solicited



    This was a lengthy rebuttal that took the Examiner step-by-step through the key points and in the process proved that Idronoxil dissolved in a lipophilic suppository is both novel and inventive.  As this method of delivery is common to all Noxopharm applications, it seems to me that patent approvals are looking good.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
6.6¢
Change
-0.004(5.71%)
Mkt cap ! $19.28M
Open High Low Value Volume
7.6¢ 7.6¢ 6.6¢ $3.396K 49.28K

Buyers (Bids)

No. Vol. Price($)
2 57227 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 11999 1
View Market Depth
Last trade - 10.52am 05/07/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.